A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants with Dementia of the A

Grants and Contracts Details

StatusFinished
Effective start/end date1/11/23 → 9/26/24

Funding

  • PPD Investigator Services LLC: $16,800.00